Novavax, Inc.

About Novavax, Inc.

Novavax is a biotechnology company focused on powering innovation and protecting global health through the development of vaccines. Their mission is to revolutionize vaccine development using cutting-edge technology to address some of the world's most challenging diseases.

Products & Services

Nuvaxovid™ COVID-19 Vaccine (2025-2026 Formula):A protein-based, non-mRNA COVID-19 vaccine approved in the U.S. for the 2025-2026 vaccination season.

COVID-19-Influenza Combination Vaccine Candidate:A vaccine candidate showing robust immune responses and good tolerability in Phase 3 trials.

Matrix-M™ Adjuvant:An adjuvant technology that enhances the body's immune response in a targeted and efficient manner.

Protein-based Nanoparticles:Engineered proteins of target pathogens used to trigger immune system recognition for vaccine development.

Specialties

Vaccine Development Protein-based Nanoparticles Matrix-M™ Adjuvant Technology COVID-19 and Influenza Vaccines

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Investment (Private Placement) T: - FT: Equity Investment (Private Placement)	A: 85000000 MR: - FA: $85 million FAN: 85000000	D: 2023-08-08 FD: 2023-08-08	1 investors
2	RT: Stock Purchase T: - FT: Stock Purchase	A: 6750000 MR: - FA: $6,750,000 FAN: 6750000	D: 2022-12-28 FD: 2022-12-28	1 investors

Equity Investment (Private Placement) Latest

2023-08-08

$85.0M

1 investor (Pro only)

Stock Purchase 2022-12-28

$6.8M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

G

Gretchen Earle

Senior Director, Global Program Management

J

Jane Shershenovich

Vice President, Chief Intellectual Property Counsel, Legal

J

John C. Jacobs

President and Chief Executive Officer

LinkedIn (Pro only)

M

Mark Casey

Executive Vice President, Chief Legal Officer

R

Rick Crowley

Executive Vice President, Chief Operations Officer

R

Ruxandra Draghia-Akli, MD, PhD

Executive Vice President, Head of Research & Development

View 18 more team members with Pro

Unlock Full Team Directory

Recent News

Novavax, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised